Dexamethasone reduces methotrexate biliary elimination and potentiates its hepatotoxicity in rats

Toxicology

Volumn 267, Issue 1-3, 2010, Pages 165-171

  Fuksa, Leos ^a   Brcakova, Eva ^a   Kolouchova, Gabriela ^a   Hirsova, Petra ^a   Hroch, Milos ^a   Cermanova, Jolana ^a   Staud, Frantisek ^b   Micuda, Stanislav ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b Charles University in Prague Faculty of Pharmacy   (Czech Republic)

Author keywords

Biliary excretion; Conjugated bilirubin; Dexamethasone; Drug transporters; Methotrexate

Indexed keywords

BILIRUBIN GLUCURONIDE; BREAST CANCER RESISTANCE PROTEIN; CARRIER PROTEIN; DEXAMETHASONE; LIVER ENZYME; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 3; PROBENECID;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BILIARY EXCRETION; BILIRUBIN BLOOD LEVEL; BOLUS INJECTION; CONTROLLED STUDY; CYTOSTASIS; DOWN REGULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG LIVER LEVEL; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; IN VIVO STUDY; KIDNEY; KIDNEY CLEARANCE; LIVER TOXICITY; LIVER WEIGHT; LOADING DRUG DOSE; MALE; NONHUMAN; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; QUANTITATIVE ANALYSIS; RAT; REPEATED DRUG DOSE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE DRUG DOSE; STEADY STATE; UPREGULATION; WESTERN BLOTTING;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BILIARY TRACT; BILIRUBIN; DEXAMETHASONE; LIVER; MALE; MEMBRANE TRANSPORT PROTEINS; METHOTREXATE; ORGAN SIZE; RATS; RATS, WISTAR;

ANIMALIA; RATTUS;

EID: 71849102008     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tox.2009.11.010     Document Type: Article

References (41)

1. Aherne G.W., Piall E., Marks V., Mould G., and White W.F. Prolongation and enhancement of serum methotrexate concentrations by probenecid. Br. Med. J. 1 (1978) 1097-1099
2. Badagnani I., Castro R.A., Taylor T.R., Brett C.M., Huang C.C., Stryke D., Kawamoto M., Johns S.J., Ferrin T.E., Carlson E.J., Burchard E.G., and Giacomini K.M. Interaction of methotrexate with organic-anion transporting polypeptide 1A2 and its genetic variants. J. Pharmacol. Exp. Ther. 318 (2006) 521-529
3. Borst P., de Wolf C., and van de Wetering K. Multidrug resistance-associated proteins 3, 4, and 5. Pflugers Arch. 453 (2007) 661-673
4. Brouwers J.R., and de Smet P.A. Pharmacokinetic-pharmacodynamic drug interactions with nonsteroidal anti-inflammatory drugs. Clin. Pharmacokinet. 27 (1994) 462-485
5. Chandra P., Johnson B.M., Zhang P., Pollack G.M., and Brouwer K.L. Modulation of hepatic canalicular or basolateral transport proteins alters hepatobiliary disposition of a model organic anion in the isolated perfused rat liver. Drug Metab. Dispos. 33 (2005) 1238-1243
6. Chen C., Scott D., Hanson E., Franco J., Berryman E., Volberg M., and Liu X. Impact of Mrp2 on the biliary excretion and intestinal absorption of furosemide, probenecid, and methotrexate using Eisai hyperbilirubinemic rats. Pharm. Res. 20 (2003) 31-37
7. Cherrington N.J., Hartley D.P., Li N., Johnson D.R., and Klaassen C.D. Organ distribution of multidrug resistance proteins 1, 2, and 3 (Mrp1, 2, and 3) mRNA and hepatic induction of Mrp3 by constitutive androstane receptor activators in rats. J. Pharmacol. Exp. Ther. 300 (2002) 97-104
8. Czock D., Keller F., Rasche F.M., and Haussler U. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin. Pharmacokinet. 44 (2005) 61-98
9. Demeule M., Jodoin J., Beaulieu E., Brossard M., and Beliveau R. Dexamethasone modulation of multidrug transporters in normal tissues. FEBS Lett. 442 (1999) 208-214
10. English J., Aherne G.W., Arendt J., and Marks V. The effect of abolition of the endogenous corticosteroid rhythm on the circadian variation in methotrexate toxicity in the rat. Cancer Chemother. Pharmacol. 19 (1987) 287-290
11. Fuksa L., Brcakova E., Cermanova J., Hroch M., Chladek J., Kolouchova G., Malakova J., Martinkova J., Staud F., and Micuda S. Amiodarone modulates pharmacokinetics of low-dose methotrexate in rats. Biopharm. Drug Dispos. 29 (2008) 289-299
12. Grim J., Chladek J., and Martinkova J. Pharmacokinetics and pharmacodynamics of methotrexate in non-neoplastic diseases. Clin. Pharmacokinet. 42 (2003) 139-151
13. Hansen H.H., Selawry O.S., Holland J.F., and McCall C.B. The variability of individual tolerance to methotrexate in cancer patients. Br. J. Cancer 25 (1971) 298-305
14. Hendel J., and Brodthagen H. Entero-hepatic cycling of methotrexate estimated by use of the d-isomer as a reference marker. Eur. J. Clin. Pharmacol. 26 (1984) 103-107
15. Iancu T.C., Shiloh H., and Dembo L. Hepatomegaly following short-term high-dose steroid therapy. J. Pediatr. Gastroenterol. Nutr. 5 (1986) 41-46
16. Jolivet J., Cowan K.H., Curt G.A., Clendeninn N.J., and Chabner B.A. The pharmacology and clinical use of methotrexate. N. Engl. J. Med. 309 (1983) 1094-1104
17. Jones B.R., Li W., Cao J., Hoffman T.A., Gerk P.M., and Vore M. The role of protein synthesis and degradation in the post-transcriptional regulation of rat multidrug resistance-associated protein 2 (Mrp2, Abcc2). Mol. Pharmacol. 68 (2005) 701-710
18. Kamisako T., Leier I., Cui Y., Konig J., Buchholz U., Hummel-Eisenbeiss J., and Keppler D. Transport of monoglucuronosyl and bisglucuronosyl bilirubin by recombinant human and rat multidrug resistance protein 2. Hepatology 30 (1999) 485-490
19. Kubitz R., Wettstein M., Warskulat U., and Haussinger D. Regulation of the multidrug resistance protein 2 in the rat liver by lipopolysaccharide and dexamethasone. Gastroenterology 116 (1999) 401-410
20. Langman G., Hall P.M., and Todd G. Role of non-alcoholic steatohepatitis in methotrexate-induced liver injury. J. Gastroenterol. Hepatol. 16 (2001) 1395-1401
21. Lee M.H., Hong I., Kim M., Lee B.H., Kim J.H., Kang K.S., Kim H.L., Yoon B.I., Chung H., Kong G., and Lee M.O. Gene expression profiles of murine fatty liver induced by the administration of methotrexate. Toxicology 249 (2008) 75-84
22. Luttringer O., Theil F.P., Lave T., Wernli-Kuratli K., Guentert T.W., and de Saizieu A. Influence of isolation procedure, extracellular matrix and dexamethasone on the regulation of membrane transporters gene expression in rat hepatocytes. Biochem. Pharmacol. 64 (2002) 1637-1650
23. Maher J.M., Cheng X., Slitt A.L., Dieter M.Z., and Klaassen C.D. Induction of the multidrug resistance-associated protein family of transporters by chemical activators of receptor-mediated pathways in mouse liver. Drug Metab. Dispos. 33 (2005) 956-962
24. Masuda M., I'Izuka Y., Yamazaki M., Nishigaki R., Kato Y., Ni'inuma K., Suzuki H., and Sugiyama Y. Methotrexate is excreted into the bile by canalicular multispecific organic anion transporter in rats. Cancer Res. 57 (1997) 3506-3510
25. McLeod H.L. Clinically relevant drug-drug interactions in oncology. Br. J. Clin. Pharmacol. 45 (1998) 539-544
26. Micuda S., Mundlova L., Mokry J., Osterreicher J., Cermanova J., Cizkova D., and Martinkova J. The effect of Mdr1 induction on the pharmacokinetics of rhodamine 123 in rats. Basic Clin. Pharmacol. Toxicol. 96 (2005) 257-258
27. Micuda S., Fuksa L., Mundlova L., Osterreicher J., Mokry J., Cermanova J., Brcakova E., Staud F., Pokorna P., and Martinkova J. Morphological and functional changes in p-glycoprotein during dexamethasone-induced hepatomegaly. Clin. Exp. Pharmacol. Physiol. 34 (2007) 296-303
28. Micuda S., Fuksa L., Brcakova E., Osterreicher J., Cermanova J., Cibicek N., Mokry J., Staud F., and Martinkova J. Zonation of multidrug resistance-associated protein 2 in rat liver after induction with dexamethasone. J. Gastroenterol. Hepatol. 23 (2008) e225-230
29. Pascussi J.M., Drocourt L., Gerbal-Chaloin S., Fabre J.M., Maurel P., and Vilarem M.J. Dual effect of dexamethasone on CYP3A4 gene expression in human hepatocytes. Sequential role of glucocorticoid receptor and pregnane X receptor. Eur. J. Biochem. 268 (2001) 6346-6358
30. Pavek P., and Dvorak Z. Xenobiotic-induced transcriptional regulation of xenobiotic metabolizing enzymes of the cytochrome P450 superfamily in human extrahepatic tissues. Curr. Drug Metab. 9 (2008) 129-143
31. Perez C., Sutow W.W., Wang Y.M., and Herson J. Evaluation of overall toxicity of high-dosage methotrexate regimens. Med. Pediatr. Oncol. 6 (1979) 219-228
32. Pfaffl M.W. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 29 (2001) e45
33. Sterba J., Valik D., and Bajciova V. High-dose methotrexate in pediatric oncology-back to bench from bedside for a while?. J. Pediatr. Hematol. Oncol. 31 (2009) 151-152
34. Takeda M., Khamdang S., Narikawa S., Kimura H., Hosoyamada M., Cha S.H., Sekine T., and Endou H. Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J. Pharmacol. Exp. Ther. 302 (2002) 666-671
35. Takeuchi A., Masuda S., Saito H., Doi T., and Inui K. Role of kidney-specific organic anion transporters in the urinary excretion of methotrexate. Kidney Int. 60 (2001) 1058-1068
36. Thatcher N.J., and Caldwell J. Origins of hepatomegaly produced by dexamethasone (DEX), pregnenolone 16 alpha-carbonitrile (PCN) and phenobarbitone (PB) in female Sprague-Dawley rats. Biochem. Soc. Trans. 22 (1994) 132S
37. Ueda K., Kato Y., Komatsu K., and Sugiyama Y. Inhibition of biliary excretion of methotrexate by probenecid in rats: quantitative prediction of interaction from in vitro data. J. Pharmacol. Exp. Ther. 297 (2001) 1036-1043
38. van Dalen E.C., and de Camargo B. Methotrexate for high-grade osteosarcoma in children and young adults. Cochrane Database Syst. Rev. (2009) CD006325
39. van Outryve S., Schrijvers D., van den Brande J., Wilmes P., Bogers J., van Marck E., and Vermorken J.B. Methotrexate-associated liver toxicity in a patient with breast cancer: case report and literature review. Neth. J. Med. 60 (2002) 216-222
40. Vlaming M.L., Pala Z., van Esch A., Wagenaar E., de Waart D.R., van de Wetering K., van der Kruijssen C.M., Oude Elferink R.P., van Tellingen O., and Schinkel A.H. Functionally overlapping roles of Abcg2 (Bcrp1) and Abcc2 (Mrp2) in the elimination of methotrexate and its main toxic metabolite 7-hydroxymethotrexate in vivo. Clin. Cancer Res. 15 (2009) 3084-3093
41. Wolff J.E., Hauch H., Kuhl J., Egeler R.M., and Jurgens H. Dexamethasone increases hepatotoxicity of MTX in children with brain tumors. Anticancer Res. 18 (1998) 2895-2899